Ask a Scientist: How to leverage novel datasets to answer complex research questions

Paul Fields is an experienced molecular and computational biologist specializing in stem cell biology and cardiogenesis. With over eight years of experience, he designs and applies both molecular biology assays and computational analyses to uncover the mechanisms of stem cell pluripotency. His expertise includes next-generation sequencing, epigenetics, and advanced cell culture techniques.

Dr. Glover is currently Chief Executive Officer of MycRx Holdings Inc., a privately held drug discovery company and serves as a consultant to the biotech industry. He has been a director of Lite Strategy (formerly MEI Pharma) since June 2013. Previously, he served as President and Chief Executive Officer of Sierra Oncology (NASDAQ: SRRA), a drug development company focused on advancing targeted therapeutics for the treatment of patients with cancer, from July 2014 through May 2020. Prior to joining Sierra, he served as President and Chief Executive Officer of YM Biosciences, an oncology drug development company, from November 2010 until its acquisition by Gilead Sciences in February 2013. Previously, Dr. Glover was President and Chief Executive Officer of Viventia Biotech, a biopharmaceutical company involved in the discovery and development of monoclonal antibody-based technologies for the treatment of cancer, which he joined after serving as an investment manager for MDS Capital, a life sciences venture capital firm. Dr. Glover holds a B.Sc. (Hons) in Chemistry from the University of East Anglia, U.K., a M.Sc. in Chemistry from the University of British Columbia, Canada, and a Ph.D. in Chemistry from Simon Fraser University, Canada.

Brad is the Co-Founder of Highlander Health, and an oncologist, trialist, entrepreneur, and product leader dedicated to driving transformation at the intersection of research and care. He most recently led product at Verily, which he joined upon Verily’s acquisition of SignalPath, a clinical research technology company he founded and led as CEO. In addition to past roles at Flatiron Health, Texas Oncology, US Oncology, and Duke University, Brad gives his passion and leadership to a wide range of philanthropic organizations, including the National Outdoor Leadership School.

Andy Moye is currently the Senior Vice President and General Manager of Data Products at Tempus. He was previously CEO and board member for Paige, a spinout company from Memorial Sloan Kettering Cancer Center in New York City.  Andy began his career as a Flight Officer in the U.S. Navy, flying missions in Iraq and the Middle East. He has worked across the molecular diagnostics, biotechnology, real-world data, and life sciences industries at the forefront of precision medicine in oncology, notably serving as Head of Commercial Operations in North America and Latin America for Philips Digital Pathology solutions, and in senior executive roles at leading healthcare companies including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Bio-systems, now part of Takara Bio. He has a Bachelor of Science in Physiology from the University of Arizona, an MBA from the University of Florida, and a PhD in Health Economics from Walden University.